The future of DNA diagnostics.
Critchfield
G C
GC
Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA.
D001294:Attitude to Health; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D004252:DNA Mutational Analysis / Q000379:methods / Q000639:trends*; D003906:Developing Countries; D005260:Female; D005544:Forecasting; D019398:Genes, BRCA1; D030342:Genetic Diseases, Inborn / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics* / Q000517:prevention & control; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000639:trends*; D006291:Health Policy; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics; D009386:Neoplastic Syndromes, Hereditary / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D009857:Oncogenes; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D012306:Risk; D014157:Transcription Factors / Q000235:genetics
D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors